Parhelia Biosciences and Sirona Dx Partner to Advance Spatial Biology Analysis

ASHLAND, Ore. and PORTLAND, Ore. – July 21, 2026 – Parhelia Biosciences and Sirona Dx have announced a strategic partnership designed to enhance the adoption of spatial biology tools within translational research, clinical trials, and precision health initiatives.

While spatial biology technologies have significantly improved the understanding of tissue architecture and cellular interactions, many current workflows remain manual, costly, and difficult to scale. These limitations often hinder reproducibility across different laboratories and create barriers to widespread clinical application.

This collaboration will combine the expertise of both companies to address these challenges. Sirona Dx brings extensive experience across various spatial biology technologies, assisting researchers in selecting and optimizing platforms and assays for specific applications. Parhelia will contribute its Spatial Station platform, a configurable automation system intended to standardize complex spatial biology workflows, reduce manual intervention, and improve consistency in studies and across research sites.

"Spatial biology has reached a point where the next challenge is generating high-quality, reproducible data at scale, not just generating data," said Nikolay Samusik, CEO of Parhelia Biosciences. "By combining Sirona's deep scientific expertise with the Spatial Station platform, we are enabling laboratories and biopharmaceutical organizations to deploy more efficient, reproducible, and accessible spatial biology workflows."

The partnership will support a wide range of spatial biology applications, including cyclic immunofluorescence and imaging mass cytometry, from discovery research through to clinical development. The integration of automation into sample preparation, assay execution, and imaging processes is expected to reduce operational variability and lower the costs associated with large-scale spatial biology programs.

As a technology-agnostic spatial biology partner, Sirona Dx works with multiple leading platforms. This collaboration with Parhelia aims to translate these workflows into standardized, automated processes suitable for consistent implementation in both research and clinical settings.

"Researchers and pharmaceutical organizations increasingly need workflows that support both scientific rigor and operational scale," stated Nasry Yassa, CEO of Sirona Dx. "Together with Parhelia, we are creating an integrated approach that helps clients maximize data quality while simplifying implementation across diverse spatial biology technologies."

The companies believe automation will be crucial for the routine use of spatial biology in translational research, clinical trials, and precision medicine. By merging scientific expertise with scalable workflow infrastructure, Sirona Dx and Parhelia intend to establish a new standard for spatial biology execution, aiming for greater reproducibility, higher throughput, and broader access to advanced tissue analytics.